Welcome to The National Law Journal's Inadmissible, a regular Q&A series with Washington, D.C., legal professionals. The interviews take a short, to-the-point look at an issue at the intersection of law and politics and highlight the type of work being led by professionals in the nation's capital. If you are interested in being profiled, reach out to [email protected].

In this edition, Skadden, Arps, Slate, Meagher & Flom partner and head of the firm's Washington, D.C., litigation practice  Jennifer Bragg discusses the legal implications of drug pricing controls following the Inflation Reduction Act—some companies may challenge the regulatory efforts in the health care sector.